Literature DB >> 11164507

Parapoxviruses are strongly inhibited in vitro by cidofovir.

P F Nettleton1, J A Gilray, H W Reid, A A Mercer.   

Abstract

Three parapoxviruses which cause orf or related diseases in humans and animals and the orthopoxvirus, vaccinia virus, were tested for their in vitro sensitivity to cidofovir. The 50% inhibitory concentration for the three parapoxviruses was between 0.21 and 0.27 microg/ml and for vaccinia was 1.32 microg/ml. The selectivity index varied from 198 to 264 for the parapoxviruses and was 42 for vaccinia virus. Virus yield assays confirmed the ability of cidofovir to reduce ortho- and parapoxvirus replication. The efficacy of cidofovir against parapoxviruses justifies its evaluation as a candidate drug for the treatment of parapoxvirus infections in humans and animals.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11164507     DOI: 10.1016/s0166-3542(00)00130-3

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  12 in total

1.  Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice.

Authors:  Graciela Andrei; Don B Gammon; Pierre Fiten; Erik De Clercq; Ghislain Opdenakker; Robert Snoeck; David H Evans
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

2.  Activities of acyclic nucleoside phosphonates against Orf virus in human and ovine cell monolayers and organotypic ovine raft cultures.

Authors:  F Dal Pozzo; G Andrei; A Holy; J Van Den Oord; A Scagliarini; E De Clercq; R Snoeck
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

3.  Antiviral activity of HPMPC (cidofovir) against orf virus infected lambs.

Authors:  A Scagliarini; C J McInnes; L Gallina; F Dal Pozzo; L Scagliarini; R Snoeck; S Prosperi; J Sales; J A Gilray; P F Nettleton
Journal:  Antiviral Res       Date:  2006-10-11       Impact factor: 5.970

4.  Antivaccinia activities of acyclic nucleoside phosphonate derivatives in epithelial cells and organotypic cultures.

Authors:  R Snoeck; A Holý; C Dewolf-Peeters; J Van Den Oord; E De Clercq; G Andrei
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

5.  Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir.

Authors:  Earl R Kern; Caroll Hartline; Emma Harden; Kathy Keith; Natalie Rodriguez; James R Beadle; Karl Y Hostetler
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

Review 6.  Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.

Authors:  Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

7.  Therapeutic paint of cidofovir/sucralfate gel combination topically administered by spraying for treatment of orf virus infections.

Authors:  Fabio Sonvico; Gaia Colombo; Laura Gallina; Fabrizio Bortolotti; Alessandra Rossi; Colin J McInnes; Gina Massimo; Paolo Colombo; Alessandra Scagliarini
Journal:  AAPS J       Date:  2009-04-21       Impact factor: 4.009

8.  Effect of 5-iodo-2'-deoxyuridine on vaccinia virus (orthopoxvirus) infections in mice.

Authors:  Johan Neyts; Erik Verbeken; Erik De Clercq
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

Review 9.  Orthopoxvirus targets for the development of new antiviral agents.

Authors:  Mark N Prichard; Earl R Kern
Journal:  Antiviral Res       Date:  2012-03-08       Impact factor: 10.103

10.  Cidofovir Activity against Poxvirus Infections.

Authors:  Graciela Andrei; Robert Snoeck
Journal:  Viruses       Date:  2010-12-22       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.